Standard BioTools Statistics
Total Valuation
LAB has a market cap or net worth of $655.65 million. The enterprise value is $285.26 million.
| Market Cap | 655.65M |
| Enterprise Value | 285.26M |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, after market close.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LAB has 370.42 million shares outstanding. The number of shares has increased by 271.93% in one year.
| Shares Outstanding | 370.42M |
| Shares Change (YoY) | +271.93% |
| Shares Change (QoQ) | +268.86% |
| Owned by Insiders (%) | 1.17% |
| Owned by Institutions (%) | 72.04% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.17 |
| Forward PS | 3.11 |
| PB Ratio | 1.14 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.51, with a Debt / Equity ratio of 0.16.
| Current Ratio | 4.51 |
| Quick Ratio | 4.14 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.99 |
Financial Efficiency
Return on equity (ROE) is -295.40% and return on invested capital (ROIC) is -17.96%.
| Return on Equity (ROE) | -295.40% |
| Return on Assets (ROA) | -30.30% |
| Return on Capital (ROIC) | -17.96% |
| Revenue Per Employee | $237,380 |
| Profits Per Employee | -$254,652 |
| Employee Count | 534 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 1.69 |
Taxes
In the past 12 months, LAB has paid $317,000 in taxes.
| Income Tax | 317,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.15% in the last 52 weeks. The beta is 1.66, so LAB's price volatility has been higher than the market average.
| Beta (5Y) | 1.66 |
| 52-Week Price Change | -10.15% |
| 50-Day Moving Average | 2.33 |
| 200-Day Moving Average | 2.35 |
| Relative Strength Index (RSI) | 29.77 |
| Average Volume (20 Days) | 4,689,422 |
Short Selling Information
The latest short interest is 13.33 million, so 3.60% of the outstanding shares have been sold short.
| Short Interest | 13.33M |
| Short Previous Month | 13.27M |
| Short % of Shares Out | 3.60% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.80 |
Income Statement
In the last 12 months, LAB had revenue of $126.76 million and -$135.98 million in losses. Loss per share was -$1.01.
| Revenue | 126.76M |
| Gross Profit | 62.30M |
| Operating Income | -120.19M |
| Pretax Income | -89.65M |
| Net Income | -135.98M |
| EBITDA | -76.45M |
| EBIT | -86.20M |
| Loss Per Share | -$1.01 |
Balance Sheet
The company has $462.28 million in cash and $91.90 million in debt, giving a net cash position of $370.39 million or $1.00 per share.
| Cash & Cash Equivalents | 462.28M |
| Total Debt | 91.90M |
| Net Cash | 370.39M |
| Net Cash Per Share | $1.00 |
| Equity (Book Value) | 577.32M |
| Book Value Per Share | 1.56 |
| Working Capital | 426.01M |
Cash Flow
In the last 12 months, operating cash flow was -$97.28 million and capital expenditures -$2.60 million, giving a free cash flow of -$99.88 million.
| Operating Cash Flow | -97.28M |
| Capital Expenditures | -2.60M |
| Free Cash Flow | -99.88M |
| FCF Per Share | -$0.34 |
Margins
Gross margin is 49.15%, with operating and profit margins of -94.82% and -107.28%.
| Gross Margin | 49.15% |
| Operating Margin | -94.82% |
| Pretax Margin | -70.73% |
| Profit Margin | -107.28% |
| EBITDA Margin | -60.31% |
| EBIT Margin | -68.00% |
| FCF Margin | -78.79% |
Dividends & Yields
LAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -271.93% |
| Shareholder Yield | -271.93% |
| Earnings Yield | -20.74% |
| FCF Yield | -15.23% |
Analyst Forecast
The average price target for LAB is $3.58, which is 102.26% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.58 |
| Price Target Difference | 102.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 31.13% |
| EPS Growth Forecast (5Y) | -61.71% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LAB has an Altman Z-Score of 0.48 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.48 |
| Piotroski F-Score | 5 |